Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The MSL - 4 Years, 200 Episodes…What’s new, What’s not
Summary
In this milestone 200th episode, Tom Caravela welcomes Sarah Snyder to delve into the evolving landscape of the Medical Science Liaison (MSL) role. Sarah shares insights from her experience, reflecting on the changes in MSL roles, titles, and key opinion leader engagement over the past four years. The discussion covers technological advancements and recruitment trends, highlighting the growing importance of MSLs in the pharmaceutical industry. Despite the lack of standardization in roles, Sarah contrasts experiences in large versus small companies and offers predictions for the future of medical affairs. The episode concludes with reflections on the significance of MSLs and gratitude to listeners.
Sarah Snyder, MSL Recruiter with The Carolan Group discusses how the MSL role has changed in the past 4 years, and how it has not.
Learn more about…
👉 Changes in KOL Engagement and Access
👉 Titles, Responsibilities and Career Ladder
👉 Resources that have emerged for MSLs (including tech and tools)
👉 What changes in hiring practices have emerged
👉 The MSL job market and factors that have affected it
👉 The universal standard for MSLs
Medical Science Liaison, MSL role evolution, KOL engagement, pharmaceutical industry trends, MSL recruitment trends
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary